Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Exclusion Criteria

• - Prior to Day 0, use of:
• a. Rituximab within 6 months
• b. Abatacept within 3 months
• c. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, Azathioprine or Mycophenolate mofetil within 2 months
• d. Etanercept, Anakinra, immunoglobulin or blood products within 28 days
• e. Prior immunotherapy, including high dose oral corticosteroids or systemic corticosteroids such as prednisone, biologics, Janus kinase (JAK) inhibitors, such as tofacitinib or investigational therapy must have completed at least 5 half-lives or 30 days, whichever is longer
• f. Prior exposure to T cell depleting agents such as Campath (alemtuzumab)
• - Evidence of any active or recent infection
• - History of systemic autoimmune disease other than Rheumatoid Arthritis; secondary Sjogren's syndrome, rheumatoid vasculitis and orther extra-articular manifestations of RA allowed
• - History of allergic reactions
• - History of anaphylaxis or allergic diathesis
• - Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram
• - Evidence of active or latent tuberculosis
• - Vaccination with live attenuated viruses within the 2 weeks prior to Day 0
• - Pregnant or breastfeeding women